Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Prices Public Stock Offering

NEW YORK (GenomeWeb News) – Luminex today announced that its public offering of 3.5 million shares of common stock, which is expected to close on June 30, will price at $19.91 per share.
 
The Austin, Texas-based firm expects to realize net proceeds of $64.5 million from the offering. It also has granted underwriters a 30-day option to acquire an additional 525,000 shares of common stock to cover any over-allotments.
 
JPMorgan and UBS are joint book-running managers for the offering, with Avondale Partners, Canaccord Adams, Leerink Swann acting as co-managers.
 
Luminex said in its preliminary prospectus for the offering that net proceeds will be used for general corporate purposes, including research and development, potential acquisitions of, or investments in, companies and technologies, capital expenditures, and additions to working capital.
 
In early Wednesday trade on the Nasdaq, shares of Luminex rose 6.6 percent to $21.22.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.